# US 2019/0375790 A1 · Multi-target peptide molecules of opioid and neuropeptide ff receptor, preparation for molecules, and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375790 A1
- Document ID: US20190375790A1
- Status: Published application
- Kind: A1
- Application number: 16/343,873
- Filed: 2017-04-13
- Published: 2019-12-12
- Earliest claimed: 2016-04-21
- Assignees: Shanghai Tianci Life Science Development Co., Ltd.
- Applicants: Shanghai Tianci Life Science Development Co., Ltd.
- Inventors: Rui WANG; Quan FANG; Zilong WANG; Biao XU
- Web page: https://patentgrep.com/patent/US20190375790A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- C07K 1/04: on carriers {(C07K1/003, C07K1/006 take precedence)}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided are nine multi-target polypeptides of an opioid and a neuropeptide FF receptor, where an amino acid is replaced on the basis of opioid peptide biphalin- and NPFF-based chimeric peptide BN-9, and acquired are the multi-target polypeptides capable of concurrently activating various opioid and NPFF system receptors.

## Claims

### Claim 1

A multi-target polypeptide of opioid and neuropeptide FF receptors, having the
Xaa1-D-Ala-Gly-Xaa2-Xaa3-Pro-Gln-Arg-Phe-NH2
where Xaa1 is Tyr or NMe-Tyr, Xaa2 is Phe or NMe-Phe: Xaa3 is Gln, Gly, Leu, Met, D-Met, D-Leu or D-Ala,

### Claim 2 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein when Xaa1 is NMe-Tyr, Xaa2 is Phe, and Xaa3 is Gln, the sequence of the multi-target polypeptide is NMe-Tyr-D-Ala-Gly-Phe-Gln-Pro-Gln-Arg-Phe-NH2.

### Claim 3 (depends on 1)

The multi-target poly peptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 2: when Xaa1 is Tyr, Xaa2 is NMe-Phe, and Xaa3 is Gln, the sequence is Tyr-D-Ala-Gly-NMe-Phe-Gln-Pro-Gln-Arg-Phe-NH2.

### Claim 4 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 3: when Xaa1 is Tyr, Xaa2 is Phe, and Xaa3 is Gly, the sequence is Tyr-D-Ala-Gly-Phe-Gly-Pro-Gln-Arg-Phe-NH2.

### Claim 5 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 4: Xaa1 is Tyr, Xaa2 is Phe, and Xaa3 is Leu, the sequence is Tyr-D-Ala-Gly-Phe-Leu-Pro-Gln-Arg-Phe-NH2.

### Claim 6 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 5: Xaa1 is Tyr, Xaa2 is Phe, and Xaa3 is Met, and the sequence is Tyr-D-Ala-Gly-Phe-Met-Pro-Gln-Arg-Phe-NH2.

### Claim 7 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 6: when Xaa1 is Tyr, Xaa2 is Phe, and Xaa3 is D-Met, the sequence is Tyr-D-Ala-Gly-Phe-D-Met-Pro-Gln-Arg-Phe-NH2.

### Claim 8 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 7: when Xaa1 is Tyr, Xaa2 is Phe, and Xaa3 is D-Leu, the sequence is Tyr-D-Ala-Gly-Phe-D-Leu-Pro-Gln-Arg-Phe-NH2.

### Claim 9 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 8: when Xaa1 is Tyr, Xaa2 is Phe, and Xaa3 is D-Ala, the sequence is Tyr-D-Ala-Gly-Phe-D-Ala-Pro-Gln-Arg-Phe-NH2.

### Claim 10 (depends on 1)

The multi-target polypeptide of opioid and neuropeptide FF receptors according to claim 1, wherein compound 9: when Xaa1 is Tyr, Xaa2 is NMe-Phe, and Xaa3 is Gly, the sequence is Tyr-D-Ala-Gly-NMe-Phe-Gly-Pro-Can-Arg-Phe-NH2.

### Claim 11 (depends on 1)

A method for synthesizing the multi-target polypeptide of opioid and a neuropeptide FF receptors according to claim 1, comprising the following process steps:
i. synthesis of polypeptide
i.i resin pretreatment: Rink-Amide-MBHA resin is stirred in dichloromethane, the resin is fully swelled, and the solvent is evaporated under reduced pressure; finally, DMF is added for washing;
i.ii removal of Fmoc group protection: in the swelled resin in which the solvent therein is evaporated, a mixed solution of hexahydropyridine, 1,8-diazabicycloundecyl-7-ene and DMF is added at a volume ratio of 1:1:98, stirred for 5 minutes, then evaporated, repeated for 3 times; finally DMF is added for washing, detected by indene, to obtain a resin with Fmoc group protection being removed;
i.iii condensation of amino acids: N-α-Fmoc protected amino acid Fmoc-AA-OH, N-hydroxybenzotriazole and O-benzotriazole-N,N,N′,N′-teramethylurea-hexafluorophosphate are completely dissolved in DMF in turn, and then diisopropylethylamine is added, mixed to obtain a mixed solution; then added into the resin with the Fmoc group protection being removed obtained in step i.ii, and stirred for 60 min in argon, and the solvent is evaporated;
repeatedly washed with DMF, and evaporated, and the Fmoc group protection is removed according to the process in step i.ii after indene-detection, to obtain a peptide resin with the Fmoc protecting group being removed;
the molar ratio of Fmoc-AA-OH and the resin with the Fmoc group protection being removed is 1:2˜1:5;
the molar ratio of N-α-Fmoc protected amino acid Fmoc-AA-OH, N-hydroxybenzotriazole, O-benzotriazole-N,N,N′,N′-tetramethylurea-hexafluorophosphate and diisopropylethylamine is 1:1:1:2;
i.iv extension of the peptide chain
according to the structural design of the polypeptide, the N-α-Fmoc protected amino acid is selected from the C-terminus in turn, and the resin with the Fmoc protecting group being removed obtained in step i.ii is subjected to the condensation of the peptide chain according to the process of step i.iii, to obtain a side chain fully protected peptide resin;
ii. cleavage of the peptide chain from the resin: the peptide resin obtained in step i.iv is washed alternately with DCM and MeOH, and the solvent is sufficiently evaporated, then a cleavage agent is added, and incubated for 2 to 3 hours at room temperature; filtered, and the filtrate is sufficiently evaporated under reduced pressure at a temperature not higher than 37° C., and then precipitated with ethyl ether at not higher than −10° C.; the supernatant is aspirated, water is added to sufficiently dissolve the precipitate, the ethyl ether is removed from the aqueous phase, and the aqueous phase is freezed and dried to obtain a white crude peptide solid powder; the cleavage agent is a solution formed by mixing trifluoroacetic acid, triisopropylsilane and water at a volume ratio of 95:2.5:2.5;
the cleavage agent is added in an amount of 18 ml of a cleavage agent per gram of the peptide resin;
iii. desalination and purification of the polypeptide: acetic acid solution with a volume concentration of 15-20% is used as a mobile phase, passed through a Sephadex G25 cross-linked dextran gel column; the main peak is collected by a UV detector and then freezed and dried to obtain a desalted peptide compound; and then the desalted peptide compound is separated and purified by reversed-phase high performance liquid chromatography column, and the main peak of the sample is collected after separation to obtain the multi-target polypeptide product.

### Claim 12 (depends on 1)

Use of the multi-target polypeptide of opioid and neuropeptide FF receptor of claim 1 for the preparation of an analgesic drug with high efficacy and low side effects.
